Entera's Phase 3 Still Not Started; First Site Activation Pushed to Late 2026

What happened

Entera Bio announced Q3 2026 results on November 6, 2026, stating that clinical preparations for the EB613 Phase 3 osteoporosis study have advanced and that first site activation is expected in late 2026. This means the registrational trial has still not begun enrollment over seven months after the March 2026 IND amendment submission, missing the internal checkpoint of first-site-initiated within 6 months. The DeepValue master report had set a September 30, 2026 exit trigger requiring FDA "may proceed" clearance and committed Phase 3 financing, but the new release provides no explicit confirmation of either. The absence of a trial registry entry or recruiting status, despite the company's framing, indicates regulatory or funding gating remains unresolved. With prior disclosed runway only through mid-Q3 2026, Entera likely had to raise capital on dilutive terms, and investors still lack proof that the Phase 3 can start without further delay.

Implication

For investors, the key takeaway is that the previous WAIT thesis has not been invalidated but has weakened because the critical catalysts (FDA clearance and financing) remain unconfirmed while the trial start slips toward year-end. The company's reliance on "preparations" language rather than concrete milestones like site initiation or first patient dosed suggests execution risk is higher than the earlier base case assumed. Existing holders should reassess position size given the dilution that likely occurred to extend the cash runway, and new buyers should demand evidence of a registered, recruiting Phase 3 with committed non-dilutive or minimally dilutive funding before establishing a position. In the absence of such proof, the bear scenario probability (trial start slipping beyond 2026 due to cash constraints) has increased relative to the original 30% weighting. Upside remains dependent on a rapid, unambiguous FDA clearance and a financing event that covers full enrollment, but those are not yet in hand.

Thesis delta

The prior WAIT thesis hinged on FDA clearance and committed financing by September 30, 2026; those milestones appear unmet, shifting the risk profile toward execution delay and heavier dilution. The disclosed 'first site activation expected in late 2026' means Phase 3 enrollment may not begin until 2027, increasing the probability that the bear scenario dominates. Consequently, the thesis moves from WAIT to a more defensive WAIT/SELL bias, requiring immediate evidence of a registered trial and non-dilutive funding to regain attractiveness.